The purpose of the study was to test the immunological and clinical effects of infusions of dendritic cells pulsed with autologous tumor lysate in patients with advanced cancer.
Patients and methods
Peripheral blood mononuclear cells from 15 patients with metastatic cancer (melanoma in 10, lung cancer in 2, renal cell carcinoma in 1, sarcoma in 1, breast cancer in 1) were harvested by leukapheresis after mobilization with GM-CSF (5 μg/kg/day s.c. for 4 days). Mononuclear cells were separated and cultured in GM-CSF (1000 U/ml) and interleukin-4 (1000 U/ml) for 7 days. Phenotype was assessed by 2-color flow cytometry and immunocytochemistry. On day 6, dendritic cells were pulsed with 1 g of fresh autologous tumor lysate for 24 h and infused intravenously. Interleukin-2 (6 million IU), interferon a (4 million IU) and GM-CSF (400 μg) were injected s.c. daily for 10 days beginning on the day of dendritic cell infusion. Treatment was repeated every 21 days for 3 courses.
Results
The morphology, immunocytochemistry and phenotype of cultured cells was consistent with dendritic cells: intense positivity for HLA-DR and CD86, with negativity for markers of other lineages, including CD3, CD4, CD8 and CD14. More than 5 × 107 dendritic cells were injected in all patients. Nine patients developed >5 mm delayed type cutaneous hypersensitivity reactions to tumor lysate ± GM-CSF after the first immunization (larger than GM-CSF in all cases). Median delayed type cutaneous hypersensitivity to lysate + GM-CSF was 3 cm after the third immunization. One melanoma patient with skin, liver, lung and bone metastases had a partial response lasting 8 months (followed by progression in the brain). Seven patients had stable disease for >3 months, and 7 had progression.
Conclusions
Infusion of tumor lysate-pulsed dendritic cells induces a strong cell-mediated antitumor immune reaction in patients with advanced cancer and has some clinical activity.
MizoguchiH.O'SheaJ.J.LongoD.L.LoefflerC.M.McVicarD.W.OchoaA.C.: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.Science, 258: 1795–1798, 1992.
2.
AmbeK.MoriM.EnjojiM.: S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis.Cancer, 63: 496–503, 1989.
3.
ChauxP.FavreN.BonnotteB.MoutetM.MartinM.MartinF.: Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors.Adv Exp Med Biol, 417: 525–528, 1997.
GabrilovichD.I.ChenH.L.GirgisK.R.CunninghamH.T.MenyG.M.NadafS.KavanaughD.CarboneD.P.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.Nat Med, 2: 1096–1103, 1996.
6.
MayordomoJ.I.ZorinaT.StorkusW.J.ZitvogelL.CelluzziC.FaloL.D.MeliefC.J.IldstadS.T.KastW.M.De LeoA.B.LotzeM.T.: Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti-tumour immunity.Nat Med, 1: 1297–1302, 1995.
7.
PorgadorA.SnyderD.GilboaE.: Induction of antitumor immunity using bone marrow-generated dendritic cells.J Immunol, 156: 2918–2926, 1996.
8.
HsuF.J.BenickeB.FagnoniF.LilesT.M.CzerwinskiD.TardiB.EnglemanE.G.LevyR.: Vaccination of patients with B cell lymphoma using autologous antigen-pulsed-dendritic cells.Nat Med, 2: 52–61, 1996.
9.
NestleF.O.AlijagicS.GillietM.SunY.GrabbeS.DummerR.BurgG.SchadendorfD.: Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells.Nat Med, 4: 328–333, 1998.
10.
BaarsA.ClaessenA.M.van der EerthweghA.J.GallH.E.StamA.G.M.MeijerS.GiacconeG.MeijerC.J.ScheperR.J.WagstaffJ.VermorkenJ.B.PinedoH.M.: Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.Ann Oncol, 11: 965–970, 2000.
11.
MillerA.B.HoogstratenB.StatquetM.WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
12.
InabaK.InabaM.RomaniN.AyaH.DeguchiM.IkeharaS.MuramatsuS.SteinmannR.M.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.J Exp Med, 176: 1693–1702, 1992.
13.
MayordomoJ.I.ZorinaT.StorkusW.ZitvogelL.Garcia-PratsM.D.De LeoA.LotzeM.T.: Bone-marrow derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.Stem Cells, 15: 94–103, 1997.
14.
Barratt-BoyesS.M.HendersonR.A.FinnO.J.: Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood.Immunology, 87: 528–534, 1996.
15.
TurleyS.J.SteinmannR.M.MellmanI.InabaK.: Propagation and culture of dendritic cells. In: Dendritic Cells, LotzeM.T.ThompsonA.W. (Eds), pp 535–554, Academic Press, San Diego, 1999.
16.
CauxC.Dezutter-DambuyantC.SmchmittD.BanchereauJ.: GM-CSF and TNF-a cooperate in the generation of dendritic Langerhans cells.Nature, 360: 258–261, 1992.
17.
CauxC.VanbervlietB B.MassacrierC.Dezutter-DambuyantC.de Saint-VisC.JacquetK.YonedaS.ImamuraD.SchmittD.BanchereauJ.: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF-α.J Exp Med, 184: 695–706, 1996.
MayordomoJ.I.LoftusD.J.SakamotoH.De CesareC.M.AppasamyP.M.LotzeM.T.StorkusW.J.AppellaE.De LeoA.B.: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.J Exp Med, 183: 1357–1365, 1996.
20.
ZitvogelL.MayordomoJ.I.TjandrawanT.De LeoA.B.ClarkeM.R.LotzeM.T.StorkusW.J.: Therapy of murine tumors with tumor derived peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and Th1-associated cytokines.J Exp Med, 183: 87–97, 1996.
21.
DhodapkarM.V.SteinmanR.M.SappM.DesaiH.FossellaC.KrasovskyJ.DonahoeS.M.DunbarP.R.CerundoloV.NixonD.F.BhardwajN.: Rapid generation of broad T cell immunity in humans after a single injection of mature dendritic cells.J Clin Invest, 104: 173–180, 1999.
22.
PorgadorA.GilboaE.: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.J Exp Med, 182: 255–260, 1995.
23.
HöltlL.RieserC.PapeshC.RamonerRBartschG.ThurnherM.: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal cell cancer.Lancet, 352: 1358, 1998.
24.
HöltlL.RieserC.PapeshC.RamonerR.HeroldM.KlockerH.RadmayrC.StenzlA.BartschG.ThurnherM.: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen-pulsed dendritic cells.J Urol, 161: 777–782, 1999.
25.
MurphyG.TjoaB.B.RagdeH.KennyG.BoyntonA.: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.Prostate, 29: 371–380, 1996.
26.
MurphyG.P.TjoaB.A.SimmonsS.J.RagdeH.RogersM.ElgamalA.KennyG.M.TraychakM.J.SalgallerM.L.BoyntonA.L.: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.Prostate, 39: 54–59, 1999.
27.
ThurnerB.HaendleI.RöderC.D.DieckmannD.KeikavoussiP.JonuleitH.BenderA.MaczekC.SchreinerD.von der DrieschP.BröckerE.B.SteinmannR.M.EnkA.KämpgenE.SchulerG.: Vaccination with Mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.J Exp Med, 190: 1669–1678, 1999.
28.
SallustoF.LanzavechiaA.: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF + IL-4 and downregulated by TNFα.J Exp Med, 179: 1109–1118, 1994.
29.
TerandoA.RoesslerB.MuleJ.: Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector.Cancer Gene Ther, 11: 165–173, 2004.
30.
KeilholzU.ScheibenbogenC.M.HoffmannU.ServetopuolouF.SchmittelA.SiehlJ.FoerslerM.H.ThielE.SchadendorfD.: Therapeutic vs adjuvant peptide vaccination: comparison of two phase I/II trials in melanoma patients.Proc Am Soc Clin Oncol, 19: 556 a (abstract 2191), 2000.
31.
SpitlerL.E.GrossbardM.L.ErnstoffM.S.SilverG.JacobsM.HayesF.A.SoongS.J.: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.J Clin Oncol, 18: 1614–1621, 2000.
32.
ShimizuK.FieldsR.C.GiedlinM.MuleJ.J.: Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.Proc Natl Acad Sci USA, 96: 2268–2273, 1999.
33.
RosenbergS.A.YangJ.C.SchwartzentruberD.J.HwuP.MarincolaF.TopalianS.RestifoN.DudleyM.SchwarzS.SpiessP.WunderlichJ.ParkhurstM.KawakamiY.SeippC.EinhornJ.WhiteD.E.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med, 4: 321–327, 1998.
34.
GilboaE.: Immunotherapy of cancer with genetically modified tumor vaccines.Sem Oncol, 23: 101–107, 1996.
35.
ZitvogelL.RegnaultA.LozierA.WolfersJ.FlamentC.TenzaD.Ricciardi-CastagnoliP.RaposoG.AmigorenaS.: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.Nat Med, 4: 594–599, 1998.
36.
WolfersJ.LozierA.RaposoG.FlamentC.RegnaultA.FaureF.TurszT.AngevinE.AmigorenaS.ZitvogelL.: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.Nat Med, 7: 297–303, 2001.
